Since I’ve featured this stock it has risen 82% and they continue further phases of testing so I expect this stock to continue higher.  They are in the enrollment phase of their clinical trials for their stroke treatment.  There continues to be acceptable levels of volume being traded and provided that this continues I would continue to be a buyer at $0.20.

This is an unpaid profile.  Please do your own due diligence before investing.

Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.

Here’s a CEO profile from YouTube with a good description of their business and exactly where the name Stem Cell comes into play and why they are in an advantageous position.

A BNN PowerBreakfast interview:

Technorati Tags: canadian penny stocks, Company Profile, Investing, sss.v, stocks, Trading